Teplizumab: position statement of Argentine Diabetes Society

Authors

  • Lidia Caracotche Pediatric Specialist Career, UBA, Lanús headquarters, Province of Buenos Aires, Argentina
  • Gloria Cerrone Institute of Immunology, Genetics and Metabolism (INIGEM), Autonomous City of Buenos Aires, Argentina
  • Alejandro de Dios José de San Martín Clinical Hospital, Autonomous City of Buenos Aires, Argentina
  • Gustavo Daniel Frechtel National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina
  • Carmen Mazza SAMIC Juan P. Garrahan Pediatric Hospital, Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina
  • Marcelo J. Perone Austral University, Province of Buenos Aires, Argentina
  • Guadalupe Pietropaolo Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires , Argentina
  • Aldana Trabucchi Institute for Humoral Immunity Studies Prof. Ricardo A Margni (IDEHU), Autonomous City of Buenos Aires, Argentina
  • Liliana Trifone University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina
  • Silvina N. Valdéz Institute for Studies of Humoral Immunity Prof. Ricardo A. Margni (IDEHU), Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v57i3.729

Keywords:

teplizumab, type 1 diabetes mellitus, prediction, prevention, position statement

Abstract

The knowledge of the etiopathogenic mechanisms of type 1 diabetes mellitus (DM1) and the possibility of identifying in early stages individuals at risk of developing the disease (presymptomatic phase or prediabetes 1) have been the bases for prevention studies for more than 3 decades.

Following the approval of the use of teplizumab (TPB) by the Food and Drug Administration/USA (FDA) in people at risk of developing DM1, the Argentine Diabetes Society has decided to select a group of experts to develop a position statement. In this sense, the following questions will be answered:

  • What are the immunological determinations used to predict DM1? What is the positive predictive value, sensitivity and specificity of autoantibodies?
  • Is prediction indicated in DM1? In what group?
  • What is TPB? What is the pharmacological efficacy and what are the adverse effects?

TPB is currently approved to delay the development of DM1 in people with stage 2 prediabetes. The population considered at risk for prediction studies are first-degree relatives of patients with DM1. Although prediction and prevention with TPB do not constitute a universal recommendation, its use can be considered in individual cases when patients are identified in stage 2 of type 1 prediabetes.

Author Biographies

Lidia Caracotche, Pediatric Specialist Career, UBA, Lanús headquarters, Province of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA), specialist in Child Nutrition, Argentine Society of Pediatrics (SAP), Coordinator of the Pediatrics Committee, Argentine Diabetes Society (SAD), Nutrition Teacher, Hospital Teaching Units, Lanús, UBA , Deputy Director of the Pediatric Specialist Career

Gloria Cerrone, Institute of Immunology, Genetics and Metabolism (INIGEM), Autonomous City of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA), Associate Professor of the Chair of Genetics, Faculty of Pharmacy and Biochemistry, UBA, Researcher at the National Scientific and Technical Research Council (CONICET)

Alejandro de Dios, José de San Martín Clinical Hospital, Autonomous City of Buenos Aires, Argentina

Medical specialist in Internal Medicine, graduated from the Argentine Society of Diabetes (SAD) Graduate School, Staff Physician at the Medical Clinic, Durand Hospital, Fellow of the Nutrition Service

Gustavo Daniel Frechtel, National Council for Scientific and Technical Research (CONICET), Autonomous City of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA), Full Professor of the Department of Medicine, Nutrition orientation, Faculty of Medicine, UBA, Head of the Nutrition Division, Hospital de Clínicas, UBA, Clinical Researcher

Carmen Mazza, SAMIC Juan P. Garrahan Pediatric Hospital, Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires, Argentina

Former head and current consultant of the Nutrition and Diabetes Section

Marcelo J. Perone, Austral University, Province of Buenos Aires, Argentina

Doctor from the National University of La Plata (UNLP), Researcher at the National Scientific and Technical Research Council (CONICET), Laboratory of Immuno-Endocrinology, Diabetes and Metabolism, Translational Medicine Research Institute (IIMT) CONICET-Austral University, Professor from the Faculty of Biomedical Sciences

Guadalupe Pietropaolo, Argentine Diabetes Society (SAD), Autonomous City of Buenos Aires , Argentina

Senior specialist in Pediatrics; Staff Physician, Sor María Ludovica La Plata Hospital (Endocrinology and Diabetes Room), Master in Diabetes; Professor at Favaloro University; Secretary of the Pediatrics Committee

Aldana Trabucchi, Institute for Humoral Immunity Studies Prof. Ricardo A Margni (IDEHU), Autonomous City of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA); Head of Practical Work, Faculty of Pharmacy and Biochemistry, Chair of Immunology; Assistant Researcher, National Council for Scientific and Technical Research (CONICET)

Liliana Trifone, University of Buenos Aires (UBA), Autonomous City of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA), Nutrition specialist UBA, specialized in Diabetes, Argentine Diabetes Society (SAD), specialist in Pediatric Nutrition, Argentine Pediatric Society (SAP); Advisor to the Pediatric Committee (SAD); Former Head of Nutrition and Diabetes Section, Ricardo Gutiérrez Children's Hospital; Director of the UBA Pediatric Nutrition Career

Silvina N. Valdéz, Institute for Studies of Humoral Immunity Prof. Ricardo A. Margni (IDEHU), Autonomous City of Buenos Aires, Argentina

Doctor from the University of Buenos Aires (UBA), Adjunct Professor, Faculty of Pharmacy and Biochemistry (UBA); Independent researcher National Council for Scientific and Technical Research (CONICET); Coordinator of the Genetics, Immunology and Prevention Committee, Argentine Diabetes Society (SAD)

References

I. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Gaglia JL, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, et al; American Diabetes Association. Classification and diagnosis of diabetes: Standards of Care in Diabetes 2023. Diabetes Care 2023; 46 (Supp-1):S19-S40. doi: 10.2337/dc23-S002.

II. Malik FS, Sauder KA, Scott I, et al. Trends in glycemic control among youth and youth adults with diabetes: The SEARCH for Diabetes in Youth Study. Diabetes Care 2022;45:285-294. doi: 10.2337/dc21-0507.

III. Miller KM, HermannJ, Foster N, et al. TID Exchange and DPV Registries. Longitudinal changes in continuous glucose monitoring use among individuals with type 1 diabetes: international comparison in the German and Austrian DPV and U.S. T1DExchange Registries. Diabetes Care 2022; 43:e1-e 2. doi: 10.2337/dc19-1214.

IV. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419.

V. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473-9. doi: 10.1001/jama.2013.6285.

VI. Krischer JP; Type 1 Diabetes TrialNet Study Group. The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013;56:1919-1924. doi: 10.1007/s00125-013-2960-7.

VII. Besser REJ, Bell KJ, Couper JJ, Ziegler AG, Wherrett DK, Knip M, Speake C, Casteels K, Driscoll KA, Jacobsen L, Craig ME, Haller MJ. ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. Pediatr Diabetes 2022 Dec;23(8):1175-1187. doi: 10.1111/pedi.13410.

VIII. Dayan CM, Besser REJ, Oram RA, Hagopian W, Vatish M, Bendor-Samuel O, Snape MD, Todd JA. Preventing type 1 diabetes in childhood. Science 2021 Jul 30;373(6554):506-510. doi: 10.1126/science.abi4742.

IX. Greenbaum CJ. A key to T1D prevention: screening and monitoring relatives as part of clinical care. Diabetes 2021 May;70(5):1029-1037. doi: 10.2337/db20-1112.

X. Winkler C, Schober E, Ziegler AG, Holl RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes 2012 Jun;13(4):308-13. doi: 10.1111/j.1399-5448.2011.00829.x.

XI. Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001;14 Suppl 1:619-22.

XII. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004 Mar 20;363(9413):925-31. doi: 10.1016/S0140-6736(04)15786-3.

XIII. Regnell SE, Lernmark A. Early prediction of autoimmune (type 1) diabetes. Diabetologia 2017;60:1370-1381. doi.:10.1007/s00125-017-4308-1

XIV. Couper JJ, Haller MJ, Ziegler AG, Knip M, Ludvigsson J, Craig ME, et al. ISPAD clinical practice consensus guidelines 2014. Phases of type 1 diabetes in children and adolescents. Pediatr Diabetes 2014;15:18-25. doi: 10.1111/pedi.12188.

XV. Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the young (TEDDY). Diabetes Care 2015;38:808-13. doi: 10.2337/dc14-2426.

XVI. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015;58:980-7. doi: 10.1007/s00125-015-3514-y.

XVII. Winkler C, Jolink M, Knopff A, Kwarteng NA, Achenbach P, Bonifacio E, Ziegler AG. Age, HLA, and sex define a marked risk of organ-specific autoimmunity in first-degree relatives of patients with type 1 diabetes. Diabetes Care 2019;42(9):1684-1691. doi: 10.2337/dc19-0315.

XVIII. Ziegler AG, Bonifacio E, BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55:1937-43. doi: 10.1007/s00125-012-2472-x.

XIX. Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012;55:1926-36. doi: 10.1007/s00125-012-2523-3.

XX. ISPAD Clinical Practice Consensus Guidelines 2022. Disponible en: https://www.ispad.org/page/ISPADGuidelines2022.

XXI. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, et al; American Diabetes Association. 3. Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes 2023. Diabetes Care 2023;46 (Supp 1):S41-S48. doi: 10.2337/dc23-S003.

XXII. Mazarello-Paes V, Barrett JK, Taylor-Robinson DC, Chesters H, Charalampopoulos D, Dunger DB, Viner RM, Stephenson TJ. Effect of early glycemic control on HbA1c tracking and development of vascular complications after 5 years of childhood onset type 1 diabetes: systematic review and meta-analysis. Pediatr Diabetes 2019 Aug;20(5):494-509. doi: 10.1111/pedi.12850.

XXIII. Sims EK, Geyer S, Johnson SB, et al. Type 1 Diabetes Trial Net Study Group. Who is enrolling? The path to monitoring Type 1 Diabetes Trial Nets Oathway Prevention. Diabetes Care 2019;42:2228-2236. doi: 10.2337/dc19-0593.

XXIV. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979 Oct 19;206(4416):347-9. doi: 10.1126/science.314668.

XXV. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985 Aug 8;313(6):337-42. doi: 10.1056/NEJM198508083130601.

XXVI. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc.Natl Acad Sci.U.S.A 1994;91:123-127. doi: 10.1073/pnas.91.1.123.

XXVII. Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992 Mar;41(3):385-91. doi: 10.2337/diab.41.3.385.

XXVIII. Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007.

XXIX. Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodríguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 2019 Aug 15; 381(7):603-613. doi: 10.1056/NEJMoa1902226. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586.

XXX. Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, et al. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves b-cell function. Diabetes Care 2023;46(10):1-9. doi: 10.2337/dc23-0675.

XXXI. Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N Engl J Med 2023 Oct 18. doi: 10.1056/NEJMoa2308743.

Downloads

Published

2023-12-12

How to Cite

Caracotche, L., Cerrone, G., de Dios, A., Frechtel, G. D., Mazza, C., Perone, M. J., Pietropaolo, G., Trabucchi, A., Trifone, L., & Valdéz, S. N. (2023). Teplizumab: position statement of Argentine Diabetes Society. Journal of the Argentine Society of Diabetes, 57(3). https://doi.org/10.47196/diab.v57i3.729

Issue

Vol. 57 No. 3 (2023): September-December

Section

Intersociety Document

License

Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Diabetes Society

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)

1 2 3 4 5 > >>